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CASE REPORT

Contrast-enhanced Ultrasound Assessment of
Treatment Response in a Patient with Multifocal
Hepatocellular Carcinoma Treated with
Transarterial Chemo and Radioembolization
Esika Savsani a, Mohamed Tantawi, MD a, Corinne E. Wessner, MBA, RDMS, RVT a, Philip Lee, MD a, Andrej
Lyshchik, MD, PhD a, Kevin Anton, MD, PhD a, Colette M. Shaw, MD a, Ji-Bin Liu, MD a, John R. Eisenbrey, PhD a, *
a

Department of Radiology, Thomas Jefferson University, Philadelphia, PA, USA

Received July 1, 2021; revision received July 22, 2021; accepted July 24, 2021
Abstract: Minimally invasive locoregional therapies have become important treatment options for patients with intermediate or
late-stage hepatocellular carcinoma (HCC) who are ineligible for surgical resection or liver transplantation. Imaging modalities
are essential for procedural guidance and for assessing treatment response thereafter. We report a unique finding of a patient with
multifocal HCC treated with transarterial radioembolization (TARE) with yttrium-90 (Y90) and transarterial chemoembolization
(TACE). We compared contrast-enhanced ultrasound (CEUS) with contrast-enhanced magnetic resonance imaging (CE-MRI)
in the evaluation of treatment response to demonstrate advantages of CEUS imaging technique and its early detection of viable
tumor.
Key words: Contrast-enhanced ultrasound; Hepatocellular carcinoma; Transarterial radioembolization; Transarterial
chemoembolization; Treatment response
Advanced Ultrasound in Diagnosis and Therapy 2021; 03: 254-257

A

lthough hepatocellular carcinoma (HCC) can
be treated in its early stages with surgical
resection, the disease is often discovered in the
intermediate or late stage, rendering patients ineligible
for resection. Thus, minimally invasive locoregional
therapies have become an alternative treatment for
these patients. Locoregional therapies can be curative,
palliative, or downstage disease progression, and can also
serve as a bridge to transplantation. Contrast-enhanced
magnetic resonance imaging (CE-MRI) or contrastenhanced computed tomography (CE-CT) has been used
as a reference standard for monitoring HCC treatment
response to locoregional therapy. Contrast-enhanced
ultrasound (CEUS) is another useful imaging technique
used to identify viable tumor and treatment efficacy.
Here we report a case of a patient with multifocal HCC
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treated with transarterial radioembolization (TARE) with
yttrium-90 (Y90) and transarterial chemoembolization
(TACE). We compared CEUS with CE-MRI in the
evaluation of treatment response to demonstrate
advantages of CEUS imaging technique and its early
detection of viable tumor.

Case Report

A 58 year-old male patient with a history of
hypertension, chronic kidney disease, coronary artery
disease, and idiopathic cirrhosis presents with an
incidental liver lesion found upon evaluation during an
unrelated admission. The patient denies smoking, illicit
drug use, or heavy alcohol use. CE-MRI demonstrated
an arterially-enhancing, diffusion-restricting segment 6/7
liver mass, with washout in the delayed phase. The mass,
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measuring 6.8 cm × 5.2 cm, was consistent with HCC
with a LIRADS-5 classification (Fig. 1). Laboratory
examinations closest to diagnosis of HCC are as follows
– Blood examination: WBC 9.2 × 103/μL, RBC 4.24 ×
103/μL, Hgb 13.9 g/dL, Hct 41.2%, Platelet 234 × 103/
μL. Liver function: ALP 154 U/L, AST 36 U/L, ALT
20 U/L, total bilirubin 0.5 mg/dL, albumin 3.5 g/dL,
AFP 321.5 ng/mL (AFP was first reported one year after
diagnosis of HCC), INR 1.0, PTT 36sec. Child-Pugh
classification was A with score of 6 points and BCLC
was Stage B.

patient’s AFP levels after TACE increased from 109.5 ng/
mL to 145.8 ng/mL in 2 months, indicative of potentially
recurrent HCC, and these levels continued to climb to
289 ng/mL over the next 3 months. A CE-MRI 10 months
after Y90 assessed the segment 6/7 post-Y90 lesion as
equivocal with potential hyperenhancement and washout
complicated with T1 hyperintensity (Fig. 7a), while the
segment 4B post-TACE lesion was again assessed as
non-viable (Fig. 7b). The rising AFP levels, the continued
non-viability of the segment 4B lesion post-TACE, and
the equivocal CE-MRI read for the segment 6/7 lesion
post-Y90 suggests that the segment 6/7 lesion is still
viable; this finding is in agreement with the CEUS exam
conducted 6 months post-Y90. Based on clinical and
CEUS results, the segment 6/7 HCC was re-evaluated
for planned Y90 1 year after the initial treatment, and
viability was confirmed during angiography (Fig. 8). The
viable tumor was successfully retreated with Y90.

Figure 1 An axial T1 baseline CE-MRI of the early arterial phase
demonstrated arterial phase hyperenhancement of the tumor (arrows)
located at segment 6/7 of the liver consistent with LIRADS-5 HCC.

The patient underwent Y90 radioembolization
(Therasphere; BTG International, London, UK) to
the segment 6/7 HCC (Fig. 2, Fig. 3). Five months
post-Y90, the treated lesion was determined to be nonviable through routine clinical standard of care CE-MRI
imaging (Fig. 4a). An incidental additional lesion was
diagnosed as a 1.5cm LIRADS-4 in segment 4B (Fig.
4b). The patient underwent TACE for this segment 4B
lesion 6 months after the initial Y90 treatment. CEUS
imaging was performed using a Logiq E9 scanner with
a curved-array C1-6 probe (GE Healthcare, Milwaukee,
WI) with a 0.2 mL bolus injection of Definity (Lantheus
Medical Imaging, North Billerica, MA). CEUS
conducted 2 weeks post-TACE, or 6 months post-Y90,
revealed no viability in the segment 4B lesion postTACE (Fig. 5a). Importantly though, CEUS data obtained
during the same bolus injection demonstrated persistent
vascularity within the segment 6/7 lesion, indicative of
viable tumor (Fig. 5b).
Contrary to the CEUS findings of viability, clinical
standard of care CE-MRI imaging 8 months after Y90
assessed the segment 6/7 lesion as non-viable, with
peripheral enhancement related to post-treatment effects
(Fig. 6a). The segment 4B lesion post-TACE was also
deemed non-viable on CE-MRI (Fig. 6b). Despite CEMRI findings of non-viability of both masses, the
AUDT 2021;03:254–257
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B

Figure 2 (A) A planning angiogram prior to Y90 pre-contrast injection
showed the location of the tumor to be treated; (B) The post-contrast
injection showed the tumor vascular supply to consider treatment mapping
for the delivery of Y90 microspheres.

Figure 3 A SPECT exam prior to Y90 demonstrated localized delivery
of the Tc99 radiotracer to the tumor (arrows) and a lung shunt fraction
of 4.05% (quantified during post-processing), indicating that Y90 is
appropriate to perform.

Discussion

Locoregional therapies play an essential role in the
HCC treatment algorithm, and can be curative, palliative,
or can downstage disease as a potential bridge to liver
255
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transplantation [1, 2]. TARE with Y90 is a locoregional
therapy which directs 20-40µm glass beads filled with
radioisotope 90Y via a catheter into the tumoral arterial
network [3]. Alternatively, TACE is a catheter-directed
locoregional therapy which delivers chemotherapy and
an embolizing agent to the tumor [4]. In many cases,
patients will have to undergo multiple locoregional
treatments, which introduces the need for earlier
detection of residual tumor [5, 6].

A

Figure 6 (A) An axial T1 CE-MRI of the early arterial phase performed
8 months after Y90 did not show arterial enhancement within the segment
6/7 Y90-treated cavity (arrows), and was called non-viable. This is
contrary to the CEUS findings of viability; (B) The segment 4B TACEtreated cavity (arrows) was deemed non-viable, in accordance with the
CEUS findings of non-viability.

A

Figure 4 An axial T1 CE-MRI of the early arterial phase performed 5
months after Y90 showed a lack of arterial phase hyperenhancement within
the tumor at segment 6/7, suggesting that the tumor is non-viable.

B

B

Figure 7 (A) An axial T1 CE-MRI of the early arterial phase performed
10 months after Y90 called the segment 6/7 tumor equivocal, with possible
hyperenhancement (arrows). This is possibly in accordance with the CEUS
findings of viability; (B) The segment 4B post-TACE lesion was again
found to be non-viable (arrows), which is in accordance with the CEUS
findings.

A
A

B

Figure 8 (A) A planning angiogram prior to the second scheduled Y90
to segment 6/7 pre-contrast injection showed the location of the tumor
to be treated; (B) The post-contrast injection demonstrated the tumor
vasculature prior to the second Y90 treatment to map out the delivery of
Y90 microspheres to the tumor.

B
Figure 5 (A) The CEUS exam performed 2 weeks post-TACE (6
months post-Y90) revealed no enhancement within the treated lesion
cavity (arrows), indicative of non-viability in the segment 4B tumor; (B)
During the same bolus injection, the CEUS demonstrated vascularity
(small arrows) within the tumor cavity (large arrows), indicative of tumor
viability in the segment 6/7 tumor.

CEUS has been studied as an alternative image
modality to CE-MRI and CE-CT in the HCC patient
population [7]. While studies have primarily focused
256

on tracking response to TACE, similar approaches to
Y90 have recently been investigated [8]. Gas-filled
microbubbles surrounded by a lipid or protein shell,
commonly known as ultrasound contrast agents (UCAs),
are used for CEUS and injected intravenously [9]. UCAs
are similar in size to erythrocytes and therefore can pass
through the pulmonary-capillary bed; due to their stable
shell surroundings, UCAs are not excreted [10]. CEUS
has distinctive benefits over CE-MRI and CE-CT such as
an absence of ionizing radiation and nephrotoxicity, high
temporal resolution, lack of artifacts typically presented
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on CE-MRI or CE-CT shortly after locoregional therapy,
and low cost [11, 12]. Due to the high temporal resolution
of CEUS, it is possible to image multiple locoregional
therapy results simultaneously. CEUS has an increased
sensitivity for detecting intramodular arterial blood flow
as compared to other image modalities [13].
In summary, this case has shown the benefits of
CEUS with accurate early detection of viable tumor
after locoregional therapy. In this case, a CEUS exam 6
months after Y90 established residual tumor (Fig. 5b),
while CE-MRI imaging 5 and 8 months after Y90 was
unable to conclusively diagnose residual tumor (Fig. 4,
Fig. 6a). Even 10 months after Y90, CE-MRI classified
the lesion as equivocal, with less certainty than CEUS
for viable tumor (Fig. 7a). These findings demonstrate
the exceptional accuracy and flexibility of using CEUS
to monitor HCC response to locoregional therapy.
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